 Fms like tyrosine kinase 3 has been considered as a potential drug target for the treatment of acute myeloid leukemia because of its high and aberrant expression in AML patients especially the patients with FLT3 ITD mutation . Initiating from a hit compound IC

@highlight Compound
@highlight was highly potent against FLT3 ITD and MV4 11 cells.
@highlight Molecular dynamic simulation of compound
@highlight provided the valuable insights into designing new FLT3 inhibitors.
@highlight Over 1000 fold elevation in FLT3 inhibitory activity was achieved through structure based drug design.
